• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

21st ISAM Congress focused on emerging trends

The congress featured several sessions on lung modeling, including the Ted Martonen session on lung models and a separate session on advanced in vitro/ex vivo lung models, with a number of attendees citing the presentation by Dan Huh of the University of Pennsylvania on the breathing lung-on-a-chip as a highlight.

Jan de Backer of Fluidda at the ISAM congress

Other presentations on lung modeling that drew attention included a presentation by Jan de Backer of Fluidda titled, “Patient-specific computational predictions of pulmonary drug delivery for guiding therapy and patient care: are we there yet?” and a talk by Worth Longest of Virginia Commonwealth University titled, “Simulating Epithelial Absorption of Dissolving Steroid Particles in the Small Airways.”

A significant number of presentations addressed local delivery of aerosol medication for lung diseases other than asthma and COPD, with entire sessions devoted to idiopathic pulmonary fibrosis and pulmonary infections. In the latter session, Sumathi Nambiar, Director of the FDA’s Division of Anti-Infective Products discussed “Antibacterial Drug Development: Challenges, Recent Developments,and Future Considerations to Improve Treatment of Lung Infections,” including a review of the FDA’s expedited review programs available for developers of inhaled antibiotics.

Nasal delivery presentations included several talks on unusual routes of delivery: Ronan Mac Loughlin of Aerogen discussed the use of high flow nasal therapy (HFNT) for delivery of medication to the lungs, and Laurent Vecellio of the University of Tours described a technique for delivery medication to the nose through the mouth during exhalation, which has been shown to result in significantly reduced lung and nasal valve deposition and an increase in deposition in the turbinates and rhinopharynx.

One of the presentations that generated a good deal of interest concerned expulsion of aerosols from the nose and lungs instead of delivery of aerosols to those organs. Lydia Bourouiba of MIT, whose work focuses on “the interface of fluid dynamics and disease transmission,” showed how her lab uses high speed imaging to visualize how the non-Newtonian fluids expelled during coughs and sneezes are aerosolized.

Share
« Previous Page 1 2 3 4 5Next page »

published on June 15, 2017

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews